Mecka | $60,000,000 | (Jun 3, 2026)
Novellia | $18,000,000 | (Jun 3, 2026)
Plot | $10,000,000 | (Jun 3, 2026)
Certified by Founder
Lodge
ADARx Pharmaceuticals Inc.
start up
United States
- San Diego, CA
- 10/08/2023
- Series C
- $200,000,000
ADARx Pharmaceuticals, Inc., located in San Diego, is a clinical stage biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx has developed proprietary RNA targeting platforms and oligonucleotide delivery technologies for inhibition, degradation, and editing disease-causing mRNA. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated diseases and central nervous system diseases. We are well-financed by a syndicate of renowned VC firms.
ADARx currently has multiple active programs in development. Our lead candidate is at the clinical stage.
- Industry Biotechnology Research
- Website https://www.adarx.com/
- LinkedIn https://www.linkedin.com/company/adarx-pharmaceuticals-inc/
KOSMOS | $5,000,000 | (Jun 3, 2026)
Phosio Corporation | $4,000,000 | (Jun 3, 2026)
StratusGrid | $3,000,000 | (Jun 3, 2026)
Subtle Medical | $33,000,000 | (Jun 3, 2026)
Tavo Biotherapeutics | $17,000,000 | (Jun 3, 2026)
Contraline | $92,500,000 | (Jun 3, 2026)
Gigaton | $26,000,000 | (Jun 3, 2026)
Westmag | $11,000,000 | (Jun 3, 2026)
Inherent | $50,000,000 | (Jun 2, 2026)